Ozenoxacin 1% regulatory update

FDA accepted for review an NDA from Medimetriks for ozenoxacin 1% cream to treat impetigo. The PDUFA date is June 22, 2017. Ozenoxacin is a non-fluorinated quinolone antibacterial that inhibits DNA gyrase and topoisomerase IV. ...